NEW YORK, May 3, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on BTX, EBIO, ECYT, and ESPR which can be accessed for free by signing up to www.wallstequities.com/registration. On Wednesday, May 02, 2018, the NASDAQ Composite ended the trading
Alameda, California-based BioTime Inc.'s stock finished Wednesday's session flat at $2.20 with a total trading volume of 315,119 shares. The stock is trading below its 50-day moving average by 13.56%. Additionally, shares of BioTime, which focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the US and Israel, have a Relative Strength Index (RSI) of 36.26. Get the full research report on BTX for free by clicking below at: www.wallstequities.com/registration/?symbol=BTX
On Wednesday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. recorded a trading volume of 12.58 million shares, which is above its three months average volume of 2.66 million shares. The stock ended the session 10.65% higher at $3.22. The Company's shares have advanced 157.60% in the last month, 209.62% in the previous three months, and 74.05% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 135.26% and 179.28%, respectively. Moreover, shares of Eleven Biotherapeutics, which focuses on the design and development of targeted protein therapeutics, have an RSI of 90.29. Get access to our top-rated research, including the free report on EBIO at: www.wallstequities.com/registration/?symbol=EBIO
West Lafayette, Indiana headquartered Endocyte Inc.'s shares closed the day 7.82% higher at $10.34. The stock recorded a trading volume of 1.57 million shares. The Company's shares have gained 22.80% in the last month, 205.01% over the previous three months, and 357.52% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 23.95% and 126.76%, respectively. Additionally, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have an RSI of 66.69.
On April 13th, 2018, research firm Jefferies initiated a 'Buy' rating on the Company's stock, with a target price of $17 per share. Click here to subscribe for a free membership which welcomes you with our report on ECYT at: www.wallstequities.com/registration/?symbol=ECYT
Shares in Ann Arbor, Michigan headquartered Esperion Therapeutics Inc. finished 35.11% lower at $45.75. The stock recorded a trading volume of 14.59 million shares, which is above its three months average volume of 606.38 thousand shares. The Company's shares have advanced 21.87% over the last twelve months. The stock is trading below its 50-day moving average by 38.20%. Furthermore, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 19.98.
On May 02nd, 2018, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Buy' to 'Underperform'. Join our big investor community at Wall St. Equities today and get your free report on ESPR at: www.wallstequities.com/registration/?symbol=ESPR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----biotime-eleven-biotherapeutics-endocyte-and-esperion-therapeutics-300641956.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All